Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV in Early Breast Cancer
NCT01298193Phase 4Completed
- Sponsor
- GEICAM
- Start
- May 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by GEICAM. Primary endpoint: Number of Participants With Complete Response (CR) in Cycle 1 at 21 days. Started May 2011; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01298193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298193.